AKT3 is an inclusion criterion in 22 clinical trials for malignant solid tumor, of which 17 are open and 5 are closed. Of the trials that contain AKT3 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), and 10 are phase 2 (9 open) [4].

AKT3 is an inclusion criterion in 7 clinical trials for breast carcinoma, of which 7 are open and 0 are closed. Of the trials that contain AKT3 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [4].

AKT3 is an inclusion criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain AKT3 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain AKT3 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [4].

AKT3 is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain AKT3 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

AKT3 is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain AKT3 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

AKT3 is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT3 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain AKT3 status and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

AKT3 is an inclusion criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT3 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [4].

AKT3 is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT3 status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

AKT3 is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT3 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT3 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for aggressive systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and aggressive systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and cancer as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and desmoid-type fibromatosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains AKT3 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for mast cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and mast cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for undifferentiated pleomorphic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT3 is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].